Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many medicines have qualified for (a) managed access and (b) interim funding under the Innovative Medicines Fund ahead of routine commissioning.
We have no plans to review the Innovative Medicines Fund’s performance. Medicines for the Fund are identified through the National Institute for Health and Care Excellence’s (NICE) appraisal process in line with the published principles. While no new non-cancer medicine has yet entered managed access through the Fund, several technologies which have proceeded to routine funding had been identified, assessed and their suitability for the Fund discussed with the relevant manufacturers.
NICE and NHS England continue to engage with industry and track the pipeline of new medicines for possible candidates. The ringfenced £340 million funding for the Fund forms part of NHS England’s overall specialised commissioning budget. Any underspend on medicines funded through the Fund is diverted to other specialised services.